Keywords: AstraZeneca, Targacept, Antidepressant, Ph III, TC-5214
Disappointment for AstraZeneca and Targacept as antidepressant fails to meet Ph III endpoint
Article | 09 November 2011
Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Targacept (Nasdaq: TRGT) yesterday reported disappointing results of the investigational antidepressant TC-5214, causing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
